What the Options Market Tells Us About CRISPR Therapeutics
High-rolling investors have positioned themselves bearish on CRISPR Therapeutics (NASDAQ:CRSP), and it's important for retail traders to take note.
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRSP often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for CRISPR Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 25% bullish and 50% bearish. Among all the options we identified, there was one put, amounting to $111,000, and 7 calls, totaling $464,666.
Projected Price Targets
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $25.0 and $110.0 for CRISPR Therapeutics, spanning the last three months.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for CRISPR Therapeutics's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across CRISPR Therapeutics's significant trades, within a strike price range of $25.0 to $110.0, over the past month.
CRISPR Therapeutics Call and Put Volume: 30-Day Overview
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CRSP | CALL | SWEEP | BEARISH | 08/15/25 | $9.6 | $9.2 | $9.27 | $60.00 | $222.8K | 3.5K | 251 |
| CRSP | PUT | TRADE | BULLISH | 01/16/26 | $44.7 | $44.2 | $44.4 | $110.00 | $111.0K | 505 | 25 |
| CRSP | CALL | SWEEP | BEARISH | 08/15/25 | $3.7 | $3.1 | $3.1 | $72.00 | $56.7K | 18 | 18 |
| CRSP | CALL | TRADE | BEARISH | 01/15/27 | $44.9 | $44.0 | $44.0 | $25.00 | $44.0K | 205 | 10 |
| CRSP | CALL | SWEEP | NEUTRAL | 08/15/25 | $3.9 | $3.8 | $3.8 | $70.00 | $43.2K | 2.2K | 159 |
About CRISPR Therapeutics
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Having examined the options trading patterns of CRISPR Therapeutics, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
Present Market Standing of CRISPR Therapeutics
- Trading volume stands at 891,759, with CRSP's price up by 1.26%, positioned at $69.0.
- RSI indicators show the stock to be may be overbought.
- Earnings announcement expected in 11 days.
Expert Opinions on CRISPR Therapeutics
5 market experts have recently issued ratings for this stock, with a consensus target price of $75.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.
* Maintaining their stance, an analyst from Chardan Capital continues to hold a Buy rating for CRISPR Therapeutics, targeting a price of $82.
* An analyst from Needham downgraded its action to Buy with a price target of $81.
* An analyst from Clear Street has revised its rating downward to Hold, adjusting the price target to $45.
* Reflecting concerns, an analyst from JMP Securities lowers its rating to Market Outperform with a new price target of $86.
* An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $81.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for CRISPR Therapeutics, Benzinga Pro gives you real-time options trades alerts.
